NCT07590661Not yet recruiting
A Study on the Therapeutic Value of Additional Left Atrial Posterior Wall Isolation Guided by Voltage Mapping in Persistent Atrial Fibrillation.
Prospective, Multicenter, Randomized Controlled Study on the Therapeutic Value of Additional Left Atrial Posterior Wall Isolation Guided by Voltage Mapping in Persistent Atrial Fibrillation.
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
This prospective, multicenter, randomized controlled study was designed to investigate the feasibility, efficacy and safety of pulsed field ablation (PFA) strategies for persistent atrial fibrillation. For patients with persistent atrial fibrillation and normal left atrial substrate, pulmonary vein isolation combined with superior vena cava isolation will be performed. For those with abnormal left atrial substrate, two strategies will be adopted: pulmonary vein isolation plus superior vena cava isolation, and pulmonary vein isolation combined with superior vena cava isolation and left atrial posterior wall isolation. Long-term follow-up will be conducted to observe the long-term clinical outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 350 (estimated)
- First submitted
- 20 Apr 2026
- Start date
- Apr 2026
- Primary completion date
- Feb 2029
- Lead sponsor
- Hangzhou Dinova EP Technology Co., Ltd
- Diseases
- Atrial fibrillation
- NCT number
- NCT07590661
What you commit to
- Study type: Interventional
- Planned participants: 350
- From Apr 2026 to the primary completion date, Feb 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Myocardial infarction (MI), coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI) within 3 months prior to enrollment.
- Previous catheter ablation or surgical ablation for atrial fibrillation.
- History of prior left atrial appendage closure, patent foramen ovale closure, atrial septal defect closure, or repair surgery.
- Current or anticipated participation in other drug or device clinical trials.
Other illness
- Atrial fibrillation is secondary to thyroid disease or other reversible factors.
- Rheumatic heart disease or the presence of moderate to severe mitral stenosis or regurgitation.
- Unstable angina.
- Contraindications to anticoagulation or history of coagulation disorders/abnormal bleeding.
- Active systemic infection.
- Life expectancy \<12 months (e.g., advanced malignancy).
- Any other condition or abnormality deemed by the investigator to warrant exclusion.
Lab values
- Left ventricular ejection fraction \<40% or New York Heart Association (NYHA) class III/IV.
- Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² or history of renal dialysis.
Other
- Evidence of left atrial or left atrial appendage thrombus on imaging examination.
- Left atrial anteroposterior diameter \>55 mm.
- Implantation of a mechanical mitral valve prosthesis or metallic annuloplasty rings.
- Presence of intracardiac thrombus, space-occupying lesions, or other abnormalities that preclude vascular access or catheter manipulation.
- Severe hepatic dysfunction.
- Pregnancy or breastfeeding.
Who the study is looking for
- Older than 18 years.
- Diagnosed as persistent atrial fibrillation (AF); Definition: At least one episode of persistent AF was recorded on dynamic electrocardiogram (ECG) data within 12 months prior to enrollment, or other clinical evidence supporting persistent AF episodes lasting more than 7 days.
- Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Yunnan Hospital Coordinator of this site? Confirm its status | Kunming | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.